Allergies News and Research

Latest Allergies News and Research

Akorn second-quarter consolidated revenue increases 24% to $20.2 million

Akorn, Inc., a niche generic pharmaceutical company, today reported financial results for the second quarter ended June 30, 2010.

4 Aug 2010

Vical second-quarter revenues decrease to $2.1 million

Vical Incorporated today reported financial results for the three months and six months ended June 30, 2010. Revenues decreased to $2.1 million for the second quarter of 2010 from $4.0 million for the second quarter of 2009, primarily as a result of a $1.5 million milestone payment in 2009 from Merck & Co., Inc., based on Merck's ongoing Phase 1 clinical-stage development of an investigational cancer vaccine.

3 Aug 2010

Health and Safety Watch launches new website to help Canadians access health-related information

Health and Safety Watch Inc., an organization established to help Canadians manage all types of health and safety hazards, today officially launched www.HealthandSafetyWatch.com, a new website designed to give Canadians easy access to real-time information about the 500-plus product, food, and drug recalls, as well as health advisories, that occur every year.

3 Aug 2010

Prognosis Health Information Systems, Excellence in Healthcare partner to improve meaningful use criteria

Hospitals can now easily leverage ChartAccess Comprehensive EMR to comply with and report on the Centers for Medicare and Medicaid Services core measures, thereby meeting "meaningful use" criteria -- thanks to a partnership between Prognosis Health Information Systems and Excellence in Healthcare, a healthcare quality assurance consulting company based in Bentonville, Ark.

3 Aug 2010

Merck reports strong bottom-line performance in second quarter

Merck & Co., Inc. today announced financial results for the second quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the second quarter of $0.86, which excludes purchase accounting adjustments, merger-related expenses, restructuring costs and the gain on AstraZeneca's asset option exercise. Second-quarter GAAP EPS was $0.24.

2 Aug 2010

Nuvo Research second-quarter revenue increases 57% to $4.2 million

Nuvo Research Inc., a drug development company focused on the research and development of drug products that are delivered into and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the quarter ended June 30, 2010.

31 Jul 2010

Angiotech reports $61.9 million total revenue for second-quarter 2010

Angiotech Pharmaceuticals, Inc. today announced its financial results for the second quarter ended June 30, 2010.

31 Jul 2010

AIDS 2010 follow-up coverage: Global HIV/AIDS funding; HIV/AIDS studies, releases

Media outlets continued to reflect on news from the International AIDS Conference-AIDS 2010, which attracted over 19,000 participants from 197 countries to Vienna last week, according to the conference blog.

30 Jul 2010

Positive results from phase I clinical trial of MultiStem in patients with AMI announced

Angiotech Pharmaceuticals, Inc. and partner Athersys, Inc. announced positive results from its phase I clinical trial of MultiStem, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction, more commonly referred to as a heart attack.

29 Jul 2010

IBM, UPMC partner to provide redesigned SmartRoom solution with service-oriented architecture

IBM and UPMC (University of Pittsburgh Medical Center) are teaming up to bring "smarter" hospital rooms to patients nationwide. Created by UPMC three years ago to bring the right patient information to the bedside when it's needed, the high-tech "smart room" now features new capabilities, namely a system for automatically organizing and prioritizing the work of nurses and other caregivers. Under a new agreement, IBM will be the exclusive sales channel for the SmartRoom solution and will help to implement the technology for customers.

29 Jul 2010

Mylan second-quarter adjusted diluted EPS increases to $0.37

Mylan Inc. today announced its financial results for the three and six months ended June 30, 2010.

29 Jul 2010

Teva Respiratory reports positive results from BDP HFA Nasal Aerosol Phase III trial in seasonal allergic rhinitis

Teva Respiratory today announced positive results from a Phase III trial evaluating the efficacy and safety of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) Nasal Aerosol in the treatment of seasonal allergic rhinitis (SAR). The study met all efficacy endpoints, demonstrating a statistically significant benefit as compared to placebo. Furthermore, the safety profile of BDP HFA Nasal Aerosol was similar to placebo.

29 Jul 2010

Athersys reports positive results from MultiStem phase I clinical trial in heart attack patients

Athersys, Inc. announced today positive results from its phase I clinical trial of MultiStem®, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. The study results, based on four months of post-treatment patient data, demonstrate that MultiStem was well tolerated at all dose levels and also suggest improvement in heart function in treated patients.

29 Jul 2010

POA releases consensus statement on CIRS-WDB

Policyholders of America released a consensus statement written by treating physicians and researchers in the field on the mechanism and treatment of illness found in people sickened by exposure to water-damaged buildings. This illness has been the subject of heated debate that has resulted in harsh allegations being lobbed at patients by experts hired by industry to cast doubt on the legitimacy of the illness.

28 Jul 2010

Regeneron second-quarter total revenues increase to $115.9 million

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the second quarter of 2010. The Company reported a net loss of $25.5 million, or $0.31 per share (basic and diluted), for the second quarter of 2010 compared with a net loss of $14.9 million, or $0.19 per share (basic and diluted), for the second quarter of 2009.

28 Jul 2010

New York Times examines questions left unanswered by microbicide trial

The New York Times examines a set of questions raised by news out of the International AIDS Conference-AIDS 2010 last week that a microbicide gel containing the antiretroviral tenofovir used by women before and after sex helped reduce their risk of HIV infection by 39 percent.

28 Jul 2010

ITelagen to host, support and manage EHR for Allergy and Asthma Associates

ITelagen, a leading provider of electronic health record (EHR) hosting and management announced that it was selected by Allergy and Asthma Associates of Northern California, San Jose, CA to host, support and manage EHR for their medical practice. The solution includes hosting of patient data in ITelagen's SAS-70 Type II certified datacenter and unlimited IT support for staff members.

28 Jul 2010

InterMune second-quarter total revenue decreases to $5.9 million

InterMune, Inc. today announced results from operations for the second quarter and six months ended June 30, 2010. InterMune also highlighted its recent clinical development and business activities, and provided forward-looking financial guidance for 2010.

28 Jul 2010

QLT second-quarter total revenue increases 15.4% to $12.4 million

QLT Inc. today reported financial results for the second quarter ended June 30, 2010. Unless specified otherwise, all amounts are in U.S. dollars and in accordance with U.S. GAAP.

27 Jul 2010

Global Fund director calls on emerging countries to invest more in programs to reduce HIV/AIDS, TB and malaria at AIDS 2010

On the final day of the International AIDS Conference-AIDS 2010 Friday, Michel Kazatchkine, executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria called upon "China, India and other fast-growing economies" to chip in to help close the funding gap in efforts to battle HIV/AIDS, Agence France-Presse reports. "Until now, these countries have been recipients of AIDS funds, not donors," the news service writes.

27 Jul 2010

Allergies News and Research

Latest Allergies News and Research

Akorn second-quarter consolidated revenue increases 24% to $20.2 million

Vical second-quarter revenues decrease to $2.1 million

Health and Safety Watch launches new website to help Canadians access health-related information

Prognosis Health Information Systems, Excellence in Healthcare partner to improve meaningful use criteria

Merck reports strong bottom-line performance in second quarter

Nuvo Research second-quarter revenue increases 57% to $4.2 million

Angiotech reports $61.9 million total revenue for second-quarter 2010

AIDS 2010 follow-up coverage: Global HIV/AIDS funding; HIV/AIDS studies, releases

Positive results from phase I clinical trial of MultiStem in patients with AMI announced

IBM, UPMC partner to provide redesigned SmartRoom solution with service-oriented architecture

Mylan second-quarter adjusted diluted EPS increases to $0.37

Teva Respiratory reports positive results from BDP HFA Nasal Aerosol Phase III trial in seasonal allergic rhinitis

Athersys reports positive results from MultiStem phase I clinical trial in heart attack patients

POA releases consensus statement on CIRS-WDB

Regeneron second-quarter total revenues increase to $115.9 million

New York Times examines questions left unanswered by microbicide trial

ITelagen to host, support and manage EHR for Allergy and Asthma Associates

InterMune second-quarter total revenue decreases to $5.9 million

QLT second-quarter total revenue increases 15.4% to $12.4 million

Global Fund director calls on emerging countries to invest more in programs to reduce HIV/AIDS, TB and malaria at AIDS 2010

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Allergies News and Research

Latest Allergies News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in